The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Does exposure matter? Association between exposure to clinical trial conduct during training and intent to participate in clinical trials post-training among oncology fellows: An ASCO State of Cancer Care in America study.
 
M. Kelsey Kirkwood
No Relationships to Disclose
 
Laura A. Levit
No Relationships to Disclose
 
Melissa Kate Accordino
Honoraria - Incrowd
Research Funding - Genentech (Inst); Novartis (Inst); Roche (Inst)
Other Relationship - Disney
 
Manali I. Patel
No Relationships to Disclose
 
David Michael Waterhouse
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AZTherapies; Bayer; Bristol-Myers Squibb; Daiichi; Eisai; EMD Serono; Exelixis; Fresenius Kabi; Gilead Sciences; Janssen Oncology; Jazz Pharmaceuticals; Lilly; McGivney Global Advisors; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi; Sanofi/Regeneron; Seagen; Takeda
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Robin Yabroff
Consulting or Advisory Role - Flatiron Health (Inst); NCCN (Inst)
 
Ishwaria M. Subbiah
Consulting or Advisory Role - MedImmune (I)
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Blueprint Medicines (I); Celgene (I); Exelixis (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Loxo (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); Takeda (I)
Travel, Accommodations, Expenses - AstraZeneca